NET PROFIT (x1000 EUR)
EMPLOYEES
NXbio Development AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
245
|
170
|
318 |
| Earnings before taxes |
-4,133
|
-1,756
|
-2,855 |
| EBITDA |
-13
|
-15
|
-4 |
| Total assets |
11,619
|
18,265
|
16,192 |
| Current assets |
11,610
|
18,256
|
16,182 |
| Current liabilities |
12
|
5
|
4 |
| Equity capital |
7,331
|
11,400
|
14,316 |
| - share capital |
340
|
339
|
369 |
| Employees (average) |
2
|
2
|
2 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
63.1%
|
62.4%
|
88.4% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-33.5%
|
-8.7%
|
-15.7% |
| Current ratio |
96750.0%
|
365120.0%
|
404550.0% |
| Return on equity (ROE) |
-56.4%
|
-15.4%
|
-19.9% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
2 |
| Chg. No. of employees % |
0%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.